# HeartBeam Inc. (NASDAQ: BEAT) Advances Toward Commercialization of Groundbreaking ECG System

* ECG data is necessary for the diagnosis of all cardiac arrhythmias in order to assess severity, implications and treatment options.
* HeartBeam is reporting that its 12-lead ECG synthesis software for arrhythmia assessment has been submitted to the U.S. Food and Drug Administration for 510(k) clearance.
* To enable smooth commercialization, the company is building the infrastructure needed to support widespread adoption.

 In the world of heart health, palpitations are common, with atrial fibrillation (“AF”) being one of the most typical sustained arrhythmias in adults (https://ibn.fm/8TSNY). HeartBeam (NASDAQ: BEAT) is on the verge of transforming how AF is detected and managed with its breakthrough, cable-free ECG technology (https://ibn.fm/B16MX).

 “Most palpitations occur during normal sinus rhythm, and AF can be the cause of palpitations,” states a Journal of Internal Medicine report. “However, it is often asymptomatic. In contrast to the majority of palpitations which are benign in nature, AF is associated with increased risk for…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/heartbeam-inc-nasdaq-beat-advances-toward-commercialization-of-groundbreaking-ecg-system/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/heartbeam-submits-breakthrough-cable-free-ecg-tech-to-fda/19659a7507e03b78364069707efe55e1) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2511/6/nukeuavh.webp)